Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of lenvatinib plus hepatic intra-arterial cisplatin for high-risk hepatocellular carcinoma beyond Milan criteria
jRCT1041220110Phase 2Recruiting
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib and cisplatin in hepatocellular carcinoma (HCC). Primary endpoint: Time to recurrence beyond the Milan criteria. Started Jan 2023; status: recruiting.
02
Drugs
lenvatinibcisplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT1041220110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041220110.